GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomind Labs Inc (OTCPK:BMNDF) » Definitions » Common Stock

BMNDF (Biomind Labs) Common Stock : $11.43 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biomind Labs Common Stock?

Biomind Labs's quarterly common stock stayed the same from Mar. 2024 ($11.10 Mil) to Jun. 2024 ($11.10 Mil) but then increased from Jun. 2024 ($11.10 Mil) to Sep. 2024 ($11.43 Mil).

Biomind Labs's annual common stock stayed the same from Dec. 2021 ($11.10 Mil) to Dec. 2022 ($11.10 Mil) and stayed the same from Dec. 2022 ($11.10 Mil) to Dec. 2023 ($11.10 Mil).


Biomind Labs Common Stock Historical Data

The historical data trend for Biomind Labs's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomind Labs Common Stock Chart

Biomind Labs Annual Data
Trend Dec21 Dec22 Dec23
Common Stock
11.10 11.10 11.10

Biomind Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.10 11.10 11.10 11.10 11.43

Biomind Labs Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Biomind Labs Business Description

Traded in Other Exchanges
Address
Camino Saravia s/n, Pando Science and Technology Park, Pando Canelones, Canelones, URY, CP 91.000
Biomind Labs Inc is a biotech Research and Development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. Biomind is developing pharmaceutical sole and combined formulations of the main natural psychedelic molecules with the aim of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications.